- Home
- FBYD vs ACIU Comparison
FBYD vs ACIU Comparison
Compare FBYD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- ACIU
- Stock Information
- Founded
- FBYD 2021
- ACIU 2003
- Country
- FBYD United States
- ACIU Switzerland
- Employees
- FBYD N/A
- ACIU N/A
- Industry
- FBYD
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FBYD
- ACIU Health Care
- Exchange
- FBYD Nasdaq
- ACIU Nasdaq
- Market Cap
- FBYD 263.6M
- ACIU 213.3M
- IPO Year
- FBYD N/A
- ACIU 2016
- Fundamental
- Price
- FBYD $6.67
- ACIU $2.28
- Analyst Decision
- FBYD
- ACIU Strong Buy
- Analyst Count
- FBYD 0
- ACIU 1
- Target Price
- FBYD N/A
- ACIU $12.00
- AVG Volume (30 Days)
- FBYD 5.7K
- ACIU 122.7K
- Earning Date
- FBYD 08-14-2025
- ACIU 11-04-2025
- Dividend Yield
- FBYD N/A
- ACIU N/A
- EPS Growth
- FBYD N/A
- ACIU N/A
- EPS
- FBYD 0.43
- ACIU N/A
- Revenue
- FBYD $7,688,000.00
- ACIU $36,362,036.00
- Revenue This Year
- FBYD N/A
- ACIU N/A
- Revenue Next Year
- FBYD N/A
- ACIU $1,022.98
- P/E Ratio
- FBYD $14.83
- ACIU N/A
- Revenue Growth
- FBYD 9.17
- ACIU 86.71
- 52 Week Low
- FBYD $3.62
- ACIU $1.43
- 52 Week High
- FBYD $13.25
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- FBYD 46.32
- ACIU 57.11
- Support Level
- FBYD $7.08
- ACIU $2.12
- Resistance Level
- FBYD $7.48
- ACIU $2.32
- Average True Range (ATR)
- FBYD 0.54
- ACIU 0.12
- MACD
- FBYD -0.01
- ACIU 0.01
- Stochastic Oscillator
- FBYD 36.35
- ACIU 78.13
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.